Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELETRIPTAN HYDROBROMIDE vs SUMATRIPTAN SUCCINATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels and inhibits release of pro-inflammatory neuropeptides.
Acute treatment of migraine with or without aura in adults
Acute treatment of migraine with or without aura,Acute treatment of cluster headache episodes
40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.
50-100 mg orally at onset of migraine; may repeat after 2 hours if needed, max 200 mg/day. 6 mg subcutaneously as a single dose; may repeat after 1 hour if needed, max 12 mg/day. 20 mg intranasally as a single dose; may repeat after 2 hours if needed, max 40 mg/day.
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 8 hours. The half-life supports a clinical duration suitable for acute migraine treatment, with no accumulation with single doses.
Terminal elimination half-life: approximately 2 hours (range 1–4 hours). Clinical context: Short half-life supports use for acute migraine attacks; no accumulation with standard dosing.
Primarily metabolized by CYP3A4; also minor contribution from CYP2C9, CYP2C19, and CYP2D6.
Hepatic via monoamine oxidase (MAO-A); some CYP450 involvement (CYP1A2, CYP3A4 minor).
Approximately 90% of the dose is eliminated in feces, with less than 10% recovered in urine. Renal excretion accounts for about 9% of total clearance, primarily as unchanged drug. Biliary/fecal elimination is the major route.
Primarily renal (60% as unchanged drug and metabolites, 40% via feces); approximately 20% unchanged in urine. Minor biliary excretion.
Approximately 85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
14–21% (low binding; primarily to albumin and alpha1-acid glycoprotein).
Volume of distribution is approximately 1.4 L/kg (range 1.0-2.0 L/kg), indicating extensive distribution into tissues beyond total body water.
2.4 L/kg (range 2.0–3.0 L/kg). Indicates extensive extravascular distribution, crossing blood-brain barrier to reach central 5-HT1 receptors.
Oral bioavailability is approximately 50% (range 30-70% due to first-pass metabolism) for the tablet formulation. Absolute bioavailability is moderate due to presystemic clearance.
Subcutaneous: 96% (complete); Oral: 15% (low due to first-pass metabolism); Intranasal: 15–17% (relative to SC); Rectal (suppository): ~20%.
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal impairment (Cr Cl <10 m L/min).
No specific dose adjustment required for GFR ≥15 m L/min. For GFR <15 m L/min, triptans are generally avoided; hemodialysis does not remove sumatriptan.
Contraindicated in severe hepatic impairment (Child-Pugh C); no adjustment for mild to moderate impairment.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). In mild to moderate impairment, no dose adjustment recommended; use with caution.
Not established; safety and efficacy in patients <18 years not studied.
Adolescents aged 12-17: 10 mg intranasally as a single dose; may repeat once after 2 hours if needed, max 20 mg/day. Pediatric use <12 years not established.
Use with caution due to potential decreased hepatic/renal function; consider lower starting dose (20 mg).
Elderly patients have increased risk of coronary artery disease; contraindicated if CAD or other vascular disease suspected. Start at low end of dosing range; monitor for adverse effects.
No FDA boxed warning.
Not recommended for use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication due to risk of coronary vasospasm.
Coronary artery vasospasm and ischemic heart disease,Cerebrovascular events (stroke, transient ischemic attack),Life-threatening serotonin syndrome (especially with SSRIs/SNRIs),Hypertensive crisis in patients with uncontrolled hypertension,Risk of myocardial ischemia in patients with risk factors
Risk of myocardial ischemia, infarction, and arrhythmia; risk of cerebrovascular events; serotonin syndrome (especially with SSRIs/SNRIs); medication overuse headache; coronary artery disease risk assessment before use.
History of ischemic heart disease or coronary artery vasospasm,Uncontrolled hypertension,Hemiplegic or basilar migraine,Use within 24 hours of another triptan or ergotamine,Concurrent use of MAO inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment (Child-Pugh C)
Ischemic heart disease, history of myocardial infarction, coronary vasospasm (Prinzmetal angina), peripheral vascular disease, cerebrovascular disease, uncontrolled hypertension, hemiplegic or basilar migraine, use within 24 hours of ergotamine derivatives or other 5-HT1 agonists, concomitant MAO-A inhibitor use or within 2 weeks of discontinuation, severe hepatic impairment.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, increasing eletriptan exposure and risk of adverse effects. No other significant food interactions reported.
No clinically significant food interactions reported. Ingestion with food may delay absorption but does not affect efficacy. Avoid alcohol during migraine attacks as it may exacerbate headache.
Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. Avoid in third trimester due to possible uterine atony or decreased placental perfusion.
Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal abnormalities (e.g., omphalocele, cranioschisis) at high doses. Second/third trimesters: No well-controlled studies; potential for uterine hypertonus and reduced placental perfusion; use only if benefit outweighs risk.
Excreted into breast milk in low amounts (M/P ratio unknown). Relative infant dose estimated at <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for irritability and sleep disturbance.
Excreted in breast milk; M/P ratio 2.1:1. Limited infant exposure; consider avoiding breastfeeding for 12 hours post-dose. Monitor infant for irritability, sleep disturbance.
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but standard dosing remains safe. Consider lowest effective dose.
No specific dose adjustment required; however, pharmacokinetic changes (increased plasma volume, altered metabolism) may reduce efficacy. Use lowest effective dose; avoid IV or high SQ doses near term due to risk of uterine hypertonus.
Eletriptan has higher lipophilicity and longer half-life than sumatriptan, potentially offering better CNS penetration and sustained efficacy. Contraindicated within 24 hours of other triptans or ergotamines. Avoid in patients with severe hepatic impairment (Child-Pugh C) as metabolism is CYP3A4-dependent. Maximum single dose 40 mg; may repeat after 2 hours if no response, but do not exceed 80 mg/day. Onset typically within 30 minutes; if first dose fails, consider alternative therapy for subsequent attacks.
Sumatriptan succinate is a serotonin 5-HT1B/1D receptor agonist used for acute migraine and cluster headache. Administer subcutaneously for fastest onset (10-15 min). Contraindicated in patients with ischemic heart disease, Prinzmetal's angina, uncontrolled hypertension, or within 24 hours of other triptans or ergotamine derivatives. Avoid within 2 weeks of MAO-A inhibitors. A second dose may be given after 1 hour if no response, but do not exceed 12 mg/24h subcutaneously (tablets: 200 mg/24h; nasal: 40 mg/24h). Injection site reactions are common but benign. Do not use for hemiplegic or basilar migraine.
Take at the first sign of migraine headache, not for prevention.,Do not take more than 80 mg in 24 hours; wait at least 2 hours between doses.,Avoid taking within 24 hours of other triptans or ergotamine medications.,Report chest pain, palpitations, or shortness of breath immediately.,Do not use if you have uncontrolled high blood pressure, coronary artery disease, or history of stroke.,Grapefruit juice may increase drug levels; avoid consumption during treatment.,Swallow tablet whole; do not crush or chew.
Take sumatriptan at the first sign of a migraine attack; do not use for prevention.,If injection, use auto-injector as directed; rotate injection sites (e.g., thigh, upper arm).,Seek emergency care if you experience chest pain, shortness of breath, irregular heartbeat, or sudden severe abdominal pain.,Do not drive or operate machinery if dizziness or drowsiness occurs after dosing.,Avoid using more than prescribed; do not combine with other triptans or ergotamine drugs within 24 hours.,Report any symptoms suggestive of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate) if taken with SSRIs or SNRIs.
"Eletriptan, a 5-HT1B/1D receptor agonist used for migraine, and ondansetron, a 5-HT3 receptor antagonist antiemetic, both increase serotonergic activity via different mechanisms. Concurrent use may lead to excessive serotonin accumulation, potentially triggering serotonin syndrome, characterized by neuromuscular excitation, autonomic instability, and altered mental status. While the interaction is mechanistically plausible, clinical reports are rare, and caution is advised particularly in patients on multiple serotonergic agents."
"Concomitant use of eletriptan, a 5-HT1B/1D receptor agonist, with maprotiline, a tetracyclic antidepressant that inhibits serotonin reuptake, may result in additive serotonergic effects. This increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients combining these agents require close monitoring for symptoms such as hyperthermia, clonus, hyperreflexia, and agitation."
"Concomitant use of eletriptan and almotriptan, both triptan-class 5-HT1B/1D receptor agonists, increases the risk of serotonin syndrome and additive vasoconstriction, including coronary vasospasm. Excessive serotonergic activity may lead to neuromuscular excitation, autonomic instability, and altered mental status, while additive arterial vasoconstriction can precipitate severe hypertension or ischemic events, especially in patients with cardiovascular risk factors."
"Concurrent use of sumatriptan, a serotonin 5-HT1B/1D receptor agonist, and rasagiline, a selective monoamine oxidase B (MAO-B) inhibitor, can lead to serotonin syndrome due to excessive serotonergic activity in the central nervous system. Rasagiline inhibits the metabolism of serotonin, while sumatriptan indirectly increases serotonin release; their combination may result in life-threatening neuromuscular excitation, autonomic instability, and altered mental status. Symptoms may include hyperthermia, rigidity, myoclonus, and rapid fluctuations in vital signs, requiring immediate medical intervention."
"Sumatriptan, a 5-HT1B/1D receptor agonist used for migraine, and sulpiride, a dopamine D2 receptor antagonist with atypical antipsychotic properties, may exhibit additive or synergistic effects on the central nervous system. This combination can potentially increase the risk of serotonin syndrome (due to sumatriptan's serotonergic activity) and may also lead to enhanced extrapyramidal symptoms or neuroleptic malignant syndrome via combined dopaminergic antagonism. Clinical outcomes may include hyperthermia, rigidity, altered mental status, and autonomic instability."
"The combination of sumatriptan (a 5-HT1B/1D receptor agonist) and paroxetine (a selective serotonin reuptake inhibitor) increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This interaction is due to additive serotonergic effects, as both drugs enhance serotonin activity in the central nervous system. Clinical outcomes range from mild symptoms (tremor, hyperreflexia, diaphoresis) to severe manifestations (hyperthermia, rigidity, seizures) and require immediate medical attention."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELETRIPTAN HYDROBROMIDE vs SUMATRIPTAN SUCCINATE, answered by our medical review team.
ELETRIPTAN HYDROBROMIDE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.. SUMATRIPTAN SUCCINATE is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels and inhibits release of pro-inflammatory neuropeptides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELETRIPTAN HYDROBROMIDE and SUMATRIPTAN SUCCINATE depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELETRIPTAN HYDROBROMIDE is: 40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.. The standard adult dose of SUMATRIPTAN SUCCINATE is: 50-100 mg orally at onset of migraine; may repeat after 2 hours if needed, max 200 mg/day. 6 mg subcutaneously as a single dose; may repeat after 1 hour if needed, max 12 mg/day. 20 mg intranasally as a single dose; may repeat after 2 hours if needed, max 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELETRIPTAN HYDROBROMIDE and SUMATRIPTAN SUCCINATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELETRIPTAN HYDROBROMIDE is classified as Category D/X. Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. A. SUMATRIPTAN SUCCINATE is classified as Category D/X. Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal abnormalities (e.g., omphalocele, cranioschisis) at high doses. Second/third trimeste. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.